2-year follow-up of a randomized controlled trial of everolimus- and paclitaxel-eluting stents for coronary revascularization in daily practice: COMPARE (Comparison of the everolimus eluting XIENCE-V stent with the paclitaxel eluting TAXUS LIBERT stent in all-comers: A randomized open label trial)

Journal of the American College of Cardiology

Volumn 58, Issue 1, 2011, Pages 11-18

  Smits, Pieter C ^a   Kedhi, Elvin ^a   Royaards, Kees Jan ^a   Joesoef, Kaiyum Sheik ^a   Wassing, Jochem ^a   Rademaker Havinga, Tessa A M ^b   McFadden, Eugene ^a  

^a Maasstad Hospital Rotterdam   (Netherlands)

^b CARDIALYSIS   (Netherlands)

Author keywords

drug eluting stent; myocardial infarction; stent thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; EVEROLIMUS; PACLITAXEL;

ADULT; ARTICLE; CLINICAL PRACTICE; CONTROLLED STUDY; DRUG EFFICACY; DRUG ELUTING STENT; DRUG SAFETY; FATALITY; FEMALE; FOLLOW UP; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STENT THROMBOSIS;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; CORONARY RESTENOSIS; DRUG-ELUTING STENTS; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MIDDLE AGED; PACLITAXEL; SIROLIMUS; THROMBOSIS; TIME FACTORS; TREATMENT OUTCOME; TUBULIN MODULATORS;

EID: 79959502100     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2011.02.023     Document Type: Article

References (13)

1. P.W. Serruys, P. Ruygrok, and J. Neuzner A randomised comparison of an everolimus-eluting coronary stent with a paclitaxel-eluting coronary stent: the SPIRIT II trial EuroIntervention 2 2006 286 294
2. G.W. Stone, M. Midei, and W. Newman Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial JAMA 299 2008 1903 1913 (Pubitemid 351574920)
3. E. Kedhi, K.S. Joesoef, and E. McFadden Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial Lancet 375 2010 201 209
4. G.W. Stone, A. Rizvi, and W. Newman Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease N Engl J Med 362 2010 1663 1674
5. Y. Onuma, P.W. Serruys, and N. Kukreja Randomized comparison between everolimus- and paclitaxel-eluting stents: pooled analysis of the 2-year clinical follow-up from the SPIRIT II and III trials Eur Heart J 31 2010 1071 1078
6. G.W. Stone, J.W. Moses, and S.G. Ellis Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents N Engl J Med 356 2007 998 1008 (Pubitemid 46376800)
7. C. Simsek, M. Magro, and E. Boersma The unrestricted use of sirolimus- and paclitaxel-eluting stents results in better clinical outcomes during 6-year follow-up than bare-metal stents: an analysis of the RESEARCH (Rapamycin-Eluting Stent Evaluated at Rotterdam Cardiology Hospital) and T-SEARCH (Taxus-Stent Evaluated at Rotterdam Cardiology Hospital) registries J Am Coll Cardiol Intv 3 2010 1051 1058
8. P. Wenaweser, J. Daemen, and M. Zwahlen Incidences and correlates of drug-eluting stent thrombosis in routine clinical practice: 4-year clinical results from a large 2-institutional cohort study J Am Coll Cardiol 52 2008 1134 1140
9. J. Fajadet, W. Wijns, and G. Laarman Long-term follow-up of the randomised controlled trial to evaluate the safety and efficacy of the zotarolimus-eluting driver coronary stent in de novo native coronary artery lesions: five-year outcomes in the ENDEAVOR II study EuroIntervention 6 2010 562 567
10. M. Joner, G. Nakazawa, and A.V. Finn Endothelial cell recovery between comparator polymer-based drug-eluting stents J Am Coll Cardiol 52 2008 333 342 (Pubitemid 352001347)
11. J.C. Lin, S.L. Tiong, and C.Y. Chen Surface characterization and platelet adhesion studies on fluorocarbons prepared by plasma-induced graft polymerization J Biomater Sci Polym Ed 11 2000 701 714
12. C.M. Nickson, P.J. Doherty, and R.L. Williams Novel polymeric coatings with the potential to control in-stent restenosisan in vitro study J Biomat Appl 24 2010 437 452
13. G.W. Stone, A. Rizvi, K. Sudhir SPIRIT Investigators Randomized comparison of everolimus- and paclitaxel-eluting stents: 2-year follow-up from the SPIRIT (Clinical Evalution of the XIENCE V Everolimus Eluting Coronary Stent System) IV trial J Am Coll Cardiol 58 2011 19 25